| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1025 | 2018 |
| Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ... Multiple Sclerosis Journal 21 (8), 1013-1024, 2015 | 384 | 2015 |
| Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial D Cadavid, M Mellion, R Hupperts, KR Edwards, PA Calabresi, J Drulović, ... The Lancet Neurology 18 (9), 845-856, 2019 | 172 | 2019 |
| Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome G Disanto, R Adiutori, R Dobson, V Martinelli, G Dalla Costa, T Runia, ... Journal of Neurology, Neurosurgery & Psychiatry 87 (2), 126-129, 2016 | 163 | 2016 |
| Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome C Matute-Blanch, LM Villar, JC Álvarez-Cermeño, K Rejdak, ... Brain 141 (4), 1085-1093, 2018 | 153 | 2018 |
| Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis LM Villar, B Casanova, N Ouamara, M Comabella, F Jalili, D Leppert, ... Annals of neurology 76 (2), 231-240, 2014 | 82 | 2014 |
| Diagnostic and prognostic value of the cerebrospinal fluid concentration of immunoglobulin free light chains in clinically isolated syndrome with conversion to multiple sclerosis G Makshakov, V Nazarov, O Kochetova, E Surkova, S Lapin, ... PLoS One 10 (11), e0143375, 2015 | 70 | 2015 |
| The effects of intrathecal rituximab on biomarkers in multiple sclerosis J Topping, R Dobson, S Lapin, A Maslyanskiy, H Kropshofer, D Leppert, ... Multiple sclerosis and related disorders 6, 49-53, 2016 | 50 | 2016 |
| COVID-19 immunopathology and the central nervous system: implication for multiple sclerosis and other autoimmune diseases with associated demyelination MK Boziki, AFA Mentis, M Shumilina, G Makshakov, E Evdoshenko, ... Brain sciences 10 (6), 345, 2020 | 49 | 2020 |
| Leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple sclerosis G Makshakov, E Magonov, N Totolyan, V Nazarov, S Lapin, A Mazing, ... Neurology research international 2017 (1), 8652463, 2017 | 48 | 2017 |
| Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study A Bar-Or, H Wiendl, X Montalban, E Alvarez, M Davydovskaya, ... Multiple Sclerosis Journal 28 (6), 910-924, 2022 | 41 | 2022 |
| CD206-targeted liposomal myelin basic protein peptides in patients with multiple sclerosis resistant to first-line disease-modifying therapies: a first-in-human, proof-of … A Belogurov Jr, K Zakharov, Y Lomakin, K Surkov, S Avtushenko, ... Neurotherapeutics 13 (4), 895-904, 2016 | 41 | 2016 |
| Concentrations of immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis V Nazarov, G Makshakov, I Kalinin, S Lapin, E Surkova, L Mikhailova, ... Immunologic Research 66, 761-767, 2018 | 19 | 2018 |
| Implications of low-titer MOG antibodies M Levy, EA Yeh, CH Hawkes, J Lechner-Scott, G Giovannoni Multiple sclerosis and related disorders 59, 2022 | 12 | 2022 |
| Dynamics of B‐Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone E Evdoshenko, A Maslyanskiy, S Lapin, L Zaslavsky, R Dobson, ... International Scholarly Research Notices 2013 (1), 748127, 2013 | 11 | 2013 |
| Diagnostic value of immunoglobulin free light chains at the debut of multiple sclerosis VD Nazarov, GS Makshakov, AV Mazing, EA Surkova, VS Krasnov, ... Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova 117 (2. Vyp. 2), 60-65, 2017 | 9 | 2017 |
| Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» NV Khachanova, AN Boyko, KZ Bakhtiyarova, YV Vlasov, EP Evdoshenko, ... Neurology, neuropsychiatry, psychosomatics 11 (4), 172-175, 2019 | 8 | 2019 |
| Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia E Evdoshenko, A Stepanova, M Shumilina, M Davydovskaya, ... PLoS One 14 (5), e0217303, 2019 | 8 | 2019 |
| Diagnostic and prognostic significance of intrathecal synthesis of immunoglobulin free light chains in multiple sclerosis VD Nazarov, SV Lapin, EA Surkova, EP Evdoshenko, GS Makshakov, ... Medical Immunology (Russia) 17 (3), 235-244, 2015 | 7 | 2015 |
| The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis EP Evdoshenko, NA Neofidov, KZ Bakhtiyarova, MV Davydovskaya, ... Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova 119 (10. Vyp. 2), 110-119, 2019 | 6 | 2019 |
